Cwm LLC Has $31.77 Million Stock Position in Medtronic PLC $MDT

Cwm LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 17.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 333,620 shares of the medical technology company’s stock after purchasing an additional 49,783 shares during the period. Cwm LLC’s holdings in Medtronic were worth $31,774,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1248 Management LLC acquired a new position in Medtronic during the 1st quarter worth about $26,000. Delos Wealth Advisors LLC bought a new position in shares of Medtronic during the second quarter worth about $27,000. Twin Tree Management LP acquired a new position in shares of Medtronic in the first quarter worth approximately $29,000. Activest Wealth Management boosted its holdings in Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the last quarter. Finally, GFG Capital LLC bought a new stake in Medtronic in the second quarter valued at approximately $36,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Price Performance

Shares of NYSE MDT opened at $96.52 on Friday. The firm has a market capitalization of $123.74 billion, a P/E ratio of 26.02, a P/E/G ratio of 2.56 and a beta of 0.71. The firm’s 50-day moving average price is $97.54 and its 200-day moving average price is $93.72. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the company posted $1.26 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Daiwa Capital Markets boosted their price target on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Jefferies Financial Group reissued a “hold” rating and set a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Royal Bank Of Canada upped their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. UBS Group lifted their price objective on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Finally, Robert W. Baird set a $103.00 price objective on Medtronic in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).